Abbott Laboratories, Inc. (ABT) has announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial is set to enroll 850 patients across 75 sites worldwide to measure pulmonary artery pressures (PAP) using Abbott's CardioMEMS HF System.The goal is to objectively identify advanced heart failure patients at high risk of mortality who could benefit from a life-saving HeartMate 3 left ventr ...